Search results
Aldosterone Synthase Inhibitors
Author(s):
Shubh K Patel
,
Hwee Teoh
,
Ahreni Saunthar
,
et al
Added:
6 months ago
Article
Author(s):
Vijay Chopra
Added:
6 months ago
Author(s):
Laibah Arshad Khan
,
Adeena Jamil
,
Stephen J Greene
,
et al
Added:
1 year ago
Author(s):
Rishi Sethi
,
Pravesh Vishwakarma
,
Akshyaya Pradhan
Added:
1 year ago
Author(s):
Massimo Iacoviello
,
Filippo M Sarullo
,
Claudio Bilato
,
et al
Added:
7 months ago
Author(s):
Vijay Chopra
Added:
8 months ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps…
View more
Thomas Kahan
Author
Author(s):
Thomas Modine
Added:
8 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Conduction System Pacing: A Fresh Look
Author(s):
Óscar Cano, Marek Jastrzębski, Pugazhendhi Vijayaraman
Start date:
Nov 13, 2024
Broadcast
Added:
5 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
